MAP4K4 and glioblastoma: We explored several kinase inhibitors that are being investigated for CNS diseases: dasatinib (Src family kinase inhibitor for glioblastoma)42,43, lapatinib (EGFR/HER2 inhibitor for glioblastoma)44,45 and prostetin (MAP4K4 inhibitor for amyotrophic lateral sclerosis and Alzheimer disease)46.